Cargando…
Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol Monkeypox Virus Challenge in Cynomolgus Macaques
BACKGROUND: Tecovirimat (ST-246) is being developed as an antiviral therapeutic for smallpox for use in the event of an accidental or intentional release. The last reported case of smallpox was 1978 but the potential for use of variola virus for biowarfare has renewed interest in smallpox antiviral...
Autores principales: | Russo, Andrew T, Grosenbach, Douglas W, Brasel, Trevor L, Baker, Robert O, Cawthon, Andrew G, Reynolds, Erin, Bailey, Tara, Kuehl, Philip J, Sugita, Victoria, Agans, Krystle, Hruby, Dennis E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151088/ https://www.ncbi.nlm.nih.gov/pubmed/29982575 http://dx.doi.org/10.1093/infdis/jiy326 |
Ejemplares similares
-
Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge()()
por: Russo, Andrew T., et al.
Publicado: (2020) -
Tecovirimat for monkeypox
por: Halani, Sheliza, et al.
Publicado: (2022) -
Experimental Infection of Cynomolgus Macaques (Macaca fascicularis) with Aerosolized Monkeypox Virus
por: Nalca, Aysegul, et al.
Publicado: (2010) -
Effect of Monkeypox Virus Preparation on the Lethality of the Intravenous Cynomolgus Macaque Model
por: Mucker, Eric M., et al.
Publicado: (2022) -
Monkeypox treatment: Is tecovirimat the answer?
por: Niaz, Faizan, et al.
Publicado: (2022)